# Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples

> **NCT05737953** · — · RECRUITING · sponsor: **Zhaoshen Li** · enrollment: 100 (estimated)

## Conditions studied

- Pancreatic Neoplasms
- DNA Methylation
- Proteome

## Interventions

- **DIAGNOSTIC_TEST:** cfDNA methylation sequencing and proteome analysis

## Key facts

- **NCT ID:** NCT05737953
- **Lead sponsor:** Zhaoshen Li
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-01
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-02-11

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05737953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05737953, "Construction of Molecular Diagnostic Marker Model for Pancreatic Cystic Tumors Based on Pancreatic Cystic Fluid Samples". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05737953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*